Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Novozymes Distribution Agreement

12 Jan 2023 07:00

RNS Number : 4546M
Plant Health Care PLC
12 January 2023
 

12 January 2023

 

Plant Health Care plc

("Plant Health Care" or the "Company")

 

 

Plant Health Care ("PHC") and Novozymes Announce Distribution Agreement to Commence First Harpin ab Commercial Sales in India 

 

 

Plant Health Care® (AIM: PHC.L) and Novozymes South Asia Pvt. Ltd. (NASDAQ OMX: NZYM-B) have signed an agreement for the exclusive distribution of Harpin ab for use in sugar cane production in India.

 

First commercial sales are expected to commence in the second half of 2023, after receipt of the required regulatory approvals. This is the first product introduced into India by PHC. India is the world's second largest producer of sugar cane with about five million hectares under cultivation. Harpin αβ has been used on more than 180,000 hectares of sugar cane in Brazil since the launch in 2018.

 

Evaluated by Novozymes in prior growing seasons in India, the application of Harpin ab to sugar cane bolstered crop yield by more than 10% on average. Harpin αβ works by triggering the plant's own self defense systems, in a manner similar to vaccinations in humans, with crops responding with improved quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased yield. Being a biological product, Harpin αβ has a very favorable human and environmental safety profile.

Jeff Tweedy, CEO of Plant Health Care, said: ‟Building on the success of our Harpin αβ product on sugar cane in Brazil, it was natural to launch the product in India, the world's second largest producer of sugar cane. Novozymes is a leading supplier of biological products to sugar cane processors in India and will be a strong distribution partner for Plant Health Care's technology. Commencing commercial sales in India will materially support continued strong revenue growth at PHC consistent with previously announced aspirations. First sales in India are expected in H2 2023 pending regulatory approvals."

 

Shanmugam Sambanthan, Novozymes India Commercial Head of Agriculture commented: "Sugarcane production must be increased in order to achieve the transition to cleaner energy sources envisaged under India's National Policy on Biofuels. Novozymes is delighted to be working with Plant Health Care to offer Indian farmers a revolutionary biostimulant, Harpin αβ, that enhances sugarcane yield and provides superior economic returns."

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

+1 919 926 1600

Cenkos Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

+44 (0) 131 220 9771

SEC Newgate (Financial Communications) Robin Tozer / Richard Bicknell / George Esmond

+44 (0)7540 10666 phc@secnewgate.co.uk

 

Novozymes Media Relations

Lina Danstrup, Head of Media Relations

 

+45 30 77 05 52

lind@novozymes.com

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. http://www.novozymes.com

 

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREAPFFFFEDEFA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.